Biotech News
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1), compared to Q3 2025 Q3 2026 net income of $58 million or $0.20 per diluted share Q3 2026 Adjusted EBITDA ( 1) increased 3.9%, or 4.0% on a constant currency basis Q3 2026 Adjusted EPS (1) of $0.29, an
